Sign in
Active, not recruitingPhase 2

FITMI - First In Treating Male Infertility

Key facts

Who runs it
Martin Blomberg Jensen
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
180 people enrolled
Started
1 Jan 2022
Ended
30 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Denosumab
  • Sodium chloride
Record updated
15 November 2024

Who can take part

Age
18 years to 60 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Other criteria

  • Inclusion Criterias:
  • Infertile men ≥ 18 years and < 60 years of age
  • Sperm concentration ≤ 20 million pr. mL
  • Serum AMH levels ≥38 pmol/L
  • The participants must have appropriate Danish or English language skills and give written informed consent; Exclusion Criterias:
  • Chronic diseases, defined as diagnosis where signs, symptoms, and treatment imply an expected long duration and lack of a cure, such as diabetes mellitus, metabolism disorders, osteoporosis, colitis, etc
  • Sperm concentration <2 million pr. mL
  • Men with current or previous malignancies, or at potential risk of testicular cancer after baseline examination and ultrasound will be excluded
  • Men with hypocalcemia at baseline, defined as ionized calcium of < 1,18 mmol/L or albumin corrected calcium < 2,17 mmol/L or total calcium < 2.14 mmol/L
  • Serum vitamin D (25OHD) levels < 25 nmol/L
  • eGFR < 60 mL/min/1,73 m2
  • Insufficient dental status
  • Vasectomy
  • Semen volume < 0.9 mL
  • Hypersensitivity to latex, Denosumab, or to any of the excipients (acetic acid, sodium hydroxide, Sorbitol (E420), Polysorbate 20) will be excluded

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This RCT aims to assess whether treatment with Denosumab can improve semen quality in infertile men selected by serum AMH as a positive predictive biomarker.

The 2 groups in the trial

  • DenosumabExisting treatment, for comparison

    Subcutaneous injection with 60 mg Denosumab once

  • PlaceboPlacebo, for comparison

    Subcutaneous injection with NaCl once

    Treatment: Sodium chloride

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of a Single-dose Denosumab on Semen Quality in Infertile Men (FITMI): A Randomized Controlled Trial
Publications
Record updated
15 November 2024